Last updated on August 2018

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Brief description of study

The purpose of this study is to determine the safety, tolerability and overall response rate of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent lung adenocarcinoma that cannot be treated with curative intent.

Clinical Study Identifier: NCT03076164

Contact Investigators or Research Sites near you

Start Over

Helena Yu, MD

Memoral Sloan Kettering Westchester
Harrison, NY United States
  Connect »